Results 61 to 70 of about 128,630 (294)

Glucagon-Like Peptide-1 and Diabetes [PDF]

Experimental Diabetes Research, 2011
This special issue was focused on the role and the effects of glucagon-like peptide-1 (GLP-1) in type 2 diabetes. This gastrointestinal hormone, which is mainly secreted after meals, enhances glucose-stimulated insulin release and inhibits food intake.
openaire   +2 more sources

Tissue‐Stimulator Platform for Electrically Stimulating Pancreatic β‐Cells for Long‐Term Functional Regulation

Advanced Functional Materials, EarlyView.
We present a tissue‐stimulator platform for seamless electrode integration with pancreatic tissue, applying uniform electrical stimulation through optimized design with biohybrid 3D printing. Advantageous effects of electrical stimulation on β‐cell function were observed, including enhanced calcium signaling, islet morphology, and maturation.
Jihwan Kim, Uijung Yong, Myungji Kim, Jaewook Kim, Yeonggwon Jo, In Kyong Shim, Song Cheol Kim, Jinah Jang   +7 more
wiley   +1 more source

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes

Journal of Diabetes
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney‐protective effect of
Richard J. MacIsaac, Philippa Trevella, Elif I. Ekinci   +2 more
doaj   +1 more source

Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents

Neural Regeneration Research, 2019
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists is a breakthrough in the field of neural regeneration research increasing glucagon like peptide-1 bioavailability, hence its neuroprotective activities.
Shaker A Mousa, Bassam M Ayoub
doaj   +1 more source

Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study [PDF]

, 2015
AIMS:Glucagon-like peptide 1 receptor agonists (GLP-1 RA) induce weight loss and reduction in adipose tissue, but the effects of GLP-1 RA on the distribution of fat deposits have been poorly investigated. METHODS: In 25 patients with type 2 diabetes (16
Carnevale, Vincenzo, Dagostino, Mariangela Pia, Fallarino, Mara, Filardi, Tiziana, Lenzi, Andrea, Mandosi, Elisabetta, Morano, Susanna, Nieddu, Luciano, Romagnoli, Elisabetta, Turinese, Irene   +9 more
core   +1 more source

Opinion: Gavage Administration of MXene as a Route‐Specific Alternative to Intravenous Injection into the Bloodstream of Laboratory Animals for Reducing Systemic Nanotoxicity Risks in Immunosuppression and Post‐Transplantation Models with Bile Acid Modification

Advanced Healthcare Materials, EarlyView.
Recent studies reported immunosuppressive properties of specific MXene nanomaterials. Their intravenous injection into the bloodstream of laboratory animals has been a common delivery method to suppress systemic inflammation and prevent transplant rejection.
Alireza Rafieerad, M. Akif Rahman, Ahmad Amiri   +2 more
wiley   +1 more source

QBP1 Peptide as a Potential Anti‐Amyloidogenic Therapy for Type 2 Diabetes: An In Vitro Study

Advanced Science, EarlyView.
The anti‐amyloidogenic peptide QBP1 effectively halts human islet amyloid polypeptide (hIAPP) aggregation, preventing the formation of toxic β‐structured intermediates. Through a combination of biophysical assays, molecular dynamics, and cell‐based studies, QBP1 is shown to preserve β‐cell viability and metabolic homeostasis, positioning it as a ...
María M. Tejero‐Ojeda, Ada Bernaus Vives, Michał Wojciechowski, Dinh Quoc Huy Pham, Mateusz Chwastyk, Mario Vallejo, Anna Novials, Douglas V. Laurents, Mariano Carrión‐Vázquez   +8 more
wiley   +1 more source

Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high‐fat, high‐sucrose diet‐fed mice

Journal of Diabetes Investigation
Aims/Introduction Imeglimin is a recently approved oral antidiabetic agent that improves insulin resistance, and promotes insulin secretion from pancreatic β‐cells.
Osamu Kikuchi, Yuichi Ikeuchi, Masaki Kobayashi, Yoko Tabei, Hiromi Yokota‐Hashimoto, Tadahiro Kitamura   +5 more
doaj   +1 more source

CARDIOVASCULAR AND HEMODYNAMIC EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 [PDF]

, 2014
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has been shown to have hemodynamic and cardioprotective capacity in addition to its better characterized glucoregulatory actions. Because of this, emerging research has focused on the ability of
Conteh, Abass M., Goodwill, Adam G., Mather, Kieren J., Noblet, Jillian N., Sassoon, Daniel, Tune, Johnathan D.   +5 more
core   +1 more source

Sulfakinin Signaling Sense Circulating Fructose and Suppresses Food Consumption via Insulin‐Like Peptide in Bactrocera Dorsalis

Advanced Science, EarlyView.
This study discovered a new pathway that tells fruit flies when to stop eating. It found that rising blood sugar (fructose) is detected by a sensor called GR43a. This triggers a chain reaction involving the satiety signal sulfakinin and its receptor, ultimately activating a final satiety signal, ILP5.
Hong‐Fei Li, Bao Dong, Zheng‐Lin Ren, Xue‐Guang Zhu, Quan Lei, Yoonseong Park, Jin‐Jun Wang, Hong‐Bo Jiang   +7 more
wiley   +1 more source